ISRG · NASDAQ · STOCK
Intuitive Surgical (ISRG) Stock Analysis
$423.92
52W $328.57 – $603.88
65/100
$149.78B
47.9
1.46
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is ISRG Bullish or Bearish?
Bullish.
Innellis AI committee rates Intuitive Surgical (ISRG) Buy with a composite score of 65/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +10.49 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -9.51 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 17.8% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- News sentiment is positive (+0.33 across 47 articles, 14d) — News
Bear Case
- P/E of 46.8 is expensive by classic value standards — Value
- Price-to-book of 11.3x prices in significant intangible value — Value
- RSI at 73 is in overbought territory — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
65/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 6%
of 192 Healthcare peers
Value Analyst
neutral
49
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 17.8% shows genuine earnings power backing the valuation
− P/E of 46.8 is expensive by classic value standards
Growth Analyst
bullish
77
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− RSI at 73 is in overbought territory
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 47 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 66.2 to 64.5.
- New bearish signals: 2 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Technical Analyst: score 58->48 (-10); +1 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
72.5
Overbought
MACD Histogram
1.619
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Mixed
Support
$396.86
Resistance
$442.72
Bollinger %B
0.95
Inside Bands
Price vs Moving Averages
EMA 9
$410.12
Above
EMA 21
$400.60
Above
EMA 50
$393.08
Above
EMA 200
$429.26
Below
Fundamental Analysis
Valuation
12
Growth
93
Profitability
95
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
47.9×
P/B Ratio
8.27×
PEG Ratio
2.26
Dividend Yield
0.00%
52W High
$603.88
52W Low
$328.57
Quality & Growth
ROE
1602.3%
ROA
1384.3%
Gross Margin
6667.9%
Operating Margin
3127.7%
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
P/E ratio of 47.9 (rich relative to a 15-40x range); Price-to-book of 8.3x; PEG ratio of 2.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 16.0%; Return on assets of 13.8%; Net margin of 28.4%; Gross margin of 66.7%; Current ratio of 4.96 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is positive (9.09); Most recent quarter beat estimates by 9.8%; 5 consecutive earnings beats; EPS growth accelerating (-1.2% -> +12.0% QoQ); Average YoY EPS growth of 27.9%; Analyst estimates rising over recent quarters
Get the Full ISRG Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →